There is increasing evidence that HDAC inhibitors may represent a useful class of therapeutic agents for HD: For example, in transgenic mouse models of HD, the HDAC class IIa isoform HDAC4 associates with mutant HTT protein and colocalizes with cytoplasmic aggregates. Here, HDAC4 is linked to Huntington disease.